Pfizer Inc. has secured a $3.2 billion agreement with the U.S. government to deliver 105 million doses of its COVID-19 vaccine, coinciding with ongoing vaccination efforts against new variants. Despite a recent share price increase of nearly 3%, the stock fell 0.7% amid broader market weaknesses and its pursuit of full U.S. approval for its antiviral treatment Paxlovid. The company anticipates approximately $32 billion in vaccine revenue for 2022, as it gears up to distribute vaccines targeting emerging variants.
“Pfizer · shares · rising · almost 3%”
“Pfizer/BioNTech · announced · a $3.2 billion contract · to supply more COVID vaccine doses to the United States”
“Pfizer/BioNTech · said · they would have a substantial amount of BA.4/BA.5 vaccine ready for distribution · by the first week of October”
“Pfizer Inc · has submitted · new drug application · for the approval of Paxlovid for patients at high risk for progression to severe illness from COVID-19”
“Pfizer Inc · is seeking · full U.S. approval for Paxlovid · true”
“Pfizer · submitted · a New Drug Application for Paxlovid · true”
“Pfizer Inc · announced · COVID-19 vaccine supply agreement · new”
“PFE shares · are · up · 3.31%”
“PFE shares · are at · $52.64 · during the market session”
“Pfizer · has been · one of the safer stocks to hold · true”
“Pfizer · has been acquiring · businesses · true”
“Pfizer · to get · stronger and more diverse · true”
.svg&width=160)
%20-%20USA%20-%20UNOCHA.svg&width=160)